Pictet Asset Management (Switzerland)’s Acadia Pharmaceuticals ACAD Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$31.3M	Buy	1,307,540 +425,265	+48%	+$9.45M	0.04%	368
2023 Q1	$16.6M	Buy	882,275 +577,731	+190%	+$11M	0.02%	506
2022 Q4	$4.85M	Buy	304,544 +81,948	+37%	+$1.28M	0.01%	747
2022 Q3	$3.64M	Sell	222,596 -625,368	-74%	-$10.1M	0.01%	805
2022 Q2	$11.9M	Buy	847,964 +395,959	+88%	+$7.39M	0.02%	566
2022 Q1	$10.9M	Buy	452,005 +323,414	+252%	+$7.83M	0.01%	629
2021 Q4	$3M	Hold	128,591	–	–	﹤0.01%	936
2021 Q3	$2.14M	Buy	+128,591	New	+$2.48M	﹤0.01%	989

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s ACAD Position: Q2 2023 in Review

Pictet Asset Management (Switzerland) increased its Acadia Pharmaceuticals (ACAD) stake by 48% in Q2 2023, buying an estimated $9.45M and bringing the position to 1,307,540 shares worth $31.3M. The position accounts for 0.04% of the portfolio, ranked #368.

Pictet Asset Management (Switzerland) first reported a position in ACAD in Q3 2021 and has held it in 8 quarters since. 236 funds tracked by Wall St. Rank hold ACAD as of Q2 2023.

Pictet Asset Management (Switzerland) held 1,307,540 shares of Acadia Pharmaceuticals worth $31.3M as of Q2 2023.
Pictet Asset Management (Switzerland) bought 425,265 Acadia Pharmaceuticals shares in Q2 2023, an estimated $9.45M.
Acadia Pharmaceuticals made up 0.04% of Pictet Asset Management (Switzerland)'s portfolio in Q2 2023, its #368 holding.
Pictet Asset Management (Switzerland) first reported a position in Acadia Pharmaceuticals in Q3 2021 and has held it in 8 quarters since.
236 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2023.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 10 Aug 2023.